Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886

RecruitingPhase 3

Sponsor: Eli Lilly and Company

Conditions: Obesity, Overweight

Interventions: Eloralintide, Placebo

Countries: United States, Argentina, Australia, Belgium, Brazil, Canada, China, Germany

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Have Body Mass Index (BMI) at screening of the following:

  * 30 kilogram per square meter (kg/m2) OR
  * 27 kg/m2 with at least one of the following weight-related health conditions at screening:

    * high blood pressure
    * dyslipidemia
    * obstructive sleep apnea, or
    * heart disease
* Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
* Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes or type 2 diabetes
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Locations (162)
  • Tuscaloosa, Alabama, United States
  • Scottsdale, Arizona, United States
  • Escondido, California, United States
  • Fountain Valley, California, United States
  • Palm Springs, California, United States
  • Rolling Hills Estates, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Tustin, California, United States
  • Waterbury, Connecticut, United States
  • Atlantis, Florida, United States
  • Miami, Florida, United States
  • Mt. Dora, Florida, United States
  • Pembroke Pines, Florida, United States
  • Pensacola, Florida, United States
  • St. Petersburg, Florida, United States
  • Dunwoody, Georgia, United States
  • Lawrenceville, Georgia, United States
  • Stockbridge, Georgia, United States
  • Honolulu, Hawaii, United States
  • West Des Moines, Iowa, United States
  • Topeka, Kansas, United States
  • Lake Charles, Louisiana, United States
  • Baltimore, Maryland, United States
  • Hyattsville, Maryland, United States
  • Quincy, Massachusetts, United States
  • Troy, Michigan, United States
  • Las Vegas, Nevada, United States
  • Warren Township, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • + 132 more on CT.gov